VistaGen Therapeutics’ (VTGN) Outperform Rating Reiterated at William Blair

William Blair reaffirmed their outperform rating on shares of VistaGen Therapeutics (NASDAQ:VTGN) in a research report released on Tuesday,RTT News reports.

Other research analysts have also issued research reports about the company. Wall Street Zen upgraded VistaGen Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, VistaGen Therapeutics presently has an average rating of “Hold”.

VistaGen Therapeutics Price Performance

Shares of VTGN opened at $4.16 on Tuesday. The company has a market cap of $127.63 million, a P/E ratio of -2.34 and a beta of 0.55. The stock has a fifty day moving average price of $3.55 and a 200 day moving average price of $2.79. VistaGen Therapeutics has a 12 month low of $1.90 and a 12 month high of $4.52.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, hitting analysts’ consensus estimates of ($0.47). The company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.22 million. As a group, research analysts anticipate that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Institutional Investors Weigh In On VistaGen Therapeutics

Hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC purchased a new stake in VistaGen Therapeutics in the 1st quarter worth about $25,000. Bank of America Corp DE lifted its stake in VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after acquiring an additional 19,331 shares in the last quarter. Marshall Wace LLP purchased a new stake in VistaGen Therapeutics in the 2nd quarter worth about $69,000. Jane Street Group LLC purchased a new stake in VistaGen Therapeutics in the 2nd quarter worth about $190,000. Finally, AdvisorShares Investments LLC lifted its stake in VistaGen Therapeutics by 27.7% in the 2nd quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock worth $406,000 after acquiring an additional 44,000 shares in the last quarter. 78.39% of the stock is owned by hedge funds and other institutional investors.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.